Oncology

Soft tissue sarcoma- a rare tumor – accounting for less than 1% of all cancers – has the major unmet need in the form of limited treatment options for patients. Cytotoxic chemotherapy has been the mainstay of therapy for decades. Active drugs such as doxorubicin, ifosfamide, gemcitabine, taxanes, and several others are administered either as single agents or in combination regimens. The most commonly used regimen is the combination of doxorubicin and ifosfamide. After 40 years, the first drug Adriamycin to get approval for the Soft tissue sarcoma treatment, Lartruvo got approved in the STS market. However, in January 2019, the US FDA recommended that patient...